BCL2L1 and myeloproliferative disorder: Activation of PI3K/AKT pathway leads to BCL-XL up-regulation and inhibition of megakaryocyte apoptosis while ERK phosphorilation activates BAD (apoptosis activator), and BCL-2 (apoptosis inhibitor), the overall result is diminished apoptosis in MPN [68].